A detailed history of Nuveen Asset Management, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 1,651,610 shares of HALO stock, worth $84.7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,651,610
Previous 1,525,202 8.29%
Holding current value
$84.7 Million
Previous $56.4 Million 19.19%
% of portfolio
0.02%
Previous 0.02%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$33.68 - $41.95 $4.26 Million - $5.3 Million
126,408 Added 8.29%
1,651,610 $67.2 Million
Q4 2023

Feb 14, 2024

SELL
$33.32 - $42.1 $654,538 - $827,012
-19,644 Reduced 1.27%
1,525,202 $56.4 Million
Q3 2023

Nov 14, 2023

BUY
$36.46 - $44.03 $6.64 Million - $8.02 Million
182,141 Added 13.37%
1,544,846 $59 Million
Q2 2023

Aug 14, 2023

BUY
$30.28 - $38.74 $3.88 Million - $4.96 Million
128,147 Added 10.38%
1,362,705 $49.2 Million
Q1 2023

May 15, 2023

BUY
$32.86 - $55.7 $7.85 Million - $13.3 Million
239,022 Added 24.01%
1,234,558 $47.1 Million
Q4 2022

Feb 14, 2023

SELL
$40.06 - $59.44 $1.6 Million - $2.38 Million
-39,987 Reduced 3.86%
995,536 $56.6 Million
Q3 2022

Nov 14, 2022

BUY
$38.53 - $51.78 $798,611 - $1.07 Million
20,727 Added 2.04%
1,035,523 $40.9 Million
Q2 2022

Aug 15, 2022

BUY
$37.35 - $48.3 $2 Million - $2.58 Million
53,462 Added 5.56%
1,014,796 $44.7 Million
Q1 2022

May 16, 2022

SELL
$31.97 - $41.06 $287,218 - $368,883
-8,984 Reduced 0.93%
961,334 $35.8 Million
Q4 2021

Feb 14, 2022

SELL
$31.82 - $40.75 $1.32 Million - $1.69 Million
-41,490 Reduced 4.1%
970,318 $39 Million
Q3 2021

Nov 12, 2021

BUY
$38.47 - $46.42 $3.6 Million - $4.34 Million
93,456 Added 10.18%
1,011,808 $41.2 Million
Q2 2021

Aug 16, 2021

BUY
$38.84 - $51.31 $1.04 Million - $1.38 Million
26,846 Added 3.01%
918,352 $41.7 Million
Q1 2021

May 17, 2021

SELL
$39.51 - $51.45 $4.91 Million - $6.39 Million
-124,205 Reduced 12.23%
891,506 $37.2 Million
Q4 2020

May 17, 2021

BUY
$25.81 - $43.62 $1.36 Million - $2.3 Million
52,637 Added 5.47%
1,015,711 $43.4 Million
Q4 2020

Feb 16, 2021

SELL
$25.81 - $43.62 $1.98 Million - $3.34 Million
-76,546 Reduced 7.36%
963,074 $41.1 Million
Q3 2020

Nov 16, 2020

BUY
$25.74 - $29.63 $309,986 - $356,834
12,043 Added 1.17%
1,039,620 $27.3 Million
Q2 2020

Aug 14, 2020

SELL
$16.25 - $26.81 $1.06 Million - $1.75 Million
-65,325 Reduced 5.98%
1,027,577 $27.5 Million
Q1 2020

May 14, 2020

SELL
$13.9 - $21.83 $4.65 Million - $7.3 Million
-334,423 Reduced 23.43%
1,092,902 $19.7 Million
Q4 2019

Feb 14, 2020

BUY
$14.93 - $19.53 $2.42 Million - $3.16 Million
161,984 Added 12.8%
1,427,325 $25.3 Million
Q3 2019

Nov 14, 2019

SELL
$15.2 - $17.69 $3.36 Million - $3.9 Million
-220,740 Reduced 14.85%
1,265,341 $19.6 Million
Q2 2019

Aug 15, 2019

BUY
$14.75 - $17.26 $21.9 Million - $25.6 Million
1,486,081 New
1,486,081 $25.5 Million
Q3 2018

Nov 13, 2018

SELL
$16.68 - $18.41 $381,688 - $421,276
-22,883 Closed
0 $0
Q2 2018

Aug 14, 2018

SELL
$16.87 - $20.3 $16,245 - $19,548
-963 Reduced 4.04%
22,883 $386,000
Q4 2017

Feb 14, 2018

BUY
$16.75 - $20.8 $399,420 - $495,996
23,846
23,846 $0

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $7.15B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.